Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Study of Lipid Parameters and MACEs in Very High-Risk ASCVD Patients
ChiCTR2500114167Phase 4Recruiting
- Sponsor
- Wuhan Asia Heart Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of evolocumab in atherosclerotic disease (2 arms), sponsored by Wuhan Asia Heart Hospital. Primary endpoint: Low-density lipoprotein cholesterol at 12 months. Started Dec 2025; status: recruiting.
02
Drugs
evolocumab
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on ChiCTR2500114167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114167.